Publications by authors named "Hasan Kobat"
Article Synopsis
- Cardiotoxicity, a significant side effect of tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), is often under-reported and can affect patients with non-small-cell lung cancer (NSCLC).
- A study at The Royal Marsden Hospital analyzed 451 patients, finding that 19.5% developed cardiotoxicity, particularly among those with prior diabetes, a history of smoking, or existing cardiovascular disease.
- Results suggest that these risk factors could interact, increasing the likelihood of cardiotoxicity, highlighting the need for better risk stratification to enhance patient care in the context of cancer treatment.
Introduction: The tyrosine-kinase inhibitor osimertinib is an oral anti-cancer agent that is used for the treatment of patients with metastatic non-small cell lung cancer harbouring sensitising mutations. Patients receiving osimertinib are at higher risk of developing cardiac toxicity, and here we present the case of a 72-year-old male who developed multiple cardiotoxicities during therapy (i.e.
View Article and Find Full Text PDFBackground.: Oncology clinical trials demonstrate the risk of cardiotoxicity but are not sufficient to reveal the true risk. In this article, we compared the incidence of cardiotoxicity of crizotinib and osimertinib from a real-world study to data reported by phase 3 clinical trials.
View Article and Find Full Text PDFCardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events.
View Article and Find Full Text PDF